A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 May 2024 Status changed from active, no longer recruiting to completed.
- 24 Sep 2021 Planned End Date changed from 13 Jun 2020 to 30 Jun 2024.
- 24 Sep 2021 Planned primary completion date changed from 13 Jun 2020 to 30 Jun 2024.